9342-8530 Québec Inc.

Equities

DGCRF

CA2519121016

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 02:21:48 21/12/2022 am IST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	CI
2016	DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2016	CI

DiagnoCure Confirms Receipt of Nomination

April 15, 2013 at 07:44 pm IST

On April 15, 2013, DiagnoCure Inc. informed its shareholders that 3 nominations have been received from a shareholder, Todd Axelrod, who is proposing Me Pierre Dozois, Paul Guay, and Hans Mäder as directors. In addition, the Board of Directors of DiagnoCure recommended its shareholders not to vote for Todd Axelrod nominees.

Latest news about 9342-8530 Québec Inc.

DiagnoCure Announces Resignation of Frederic Boivin as Interim CFO, Effective March 28, 2016	14/16/14	CI
DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2016	12/16/12	CI
Gen-Probe Incorporated completed the acquisition of assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc..	17/16/17	CI
DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended October 31, 2015; Reports Impairment of Intangible Asset for the Fourth Quarter Ended October 31, 2015	22/16/22	CI
Gen-Probe Incorporated entered into an asset purchase agreement to acquire all assets related to PCA3 prostate cancer biomarker from DiagnoCure Inc. for CAD 6.5 million.	23/15/23	CI
DiagnoCure Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2015	11/15/11	CI
DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2015	22/15/22	CI
DiagnoCure, Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2015	12/15/12	CI
DiagnoCure Inc. Announces Board Changes	12/15/12	CI
DiagnoCure, Inc. Reports Consolidated Financial Results for the First Quarter Ended January 31, 2015	06/15/06	CI
DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Fiscal Year Ended October 31, 2014	24/15/24	CI
DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014	12/14/12	CI
DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2014	13/14/13	CI
DiagnoCure Inc. Announces Earnings Results for the Second Quarter Ended April 30, 2014	05/14/05	CI
DiagnoCure, Inc. Reports Consolidated Earnings Results for the First Quarter Ended January 31, 2014	15/14/15	CI
Transcript : DiagnoCure Inc., Q4 2013 Earnings Call, Jan 16, 2014	17/14/17
DiagnoCure, Inc. Reports Earnings Results for the Fourth Quarter 2013 and Fiscal Year Ended October 31, 2013	17/14/17	CI
DiagnoCure Inc. Announces Resignation of Chantal Miklosi as CFO Effective October 11, 2013	01/13/01	CI
Transcript : DiagnoCure Inc., Q3 2013 Earnings Call, Sep 04, 2013	05/13/05
DiagnoCure Inc. Announces Earnings Results for the Third Quarter Ended July 31, 2013	05/13/05	CI
DiagnoCure Inc. Appoints Richard Bordeleau as Senior Advisor, Effective September 1, 2013	20/13/20	CI
Transcript : DiagnoCure Inc., Q2 2013 Earnings Call, Jun 03, 2013	04/13/04
DiagnoCure Inc. Announces Earnings Results for the Second Quarter Ended April 30, 2013	04/13/04	CI
DiagnoCure Reports Data from a New Study on GCC Assay	03/13/03	CI
Declaration of Voting Results by DiagnoCure	29/13/29	CI

Chart 9342-8530 Québec Inc.

Duration

Period

More charts

Company Profile

9342-8530 Quebec Inc is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling, or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
9342-8530 QUÉBEC INC.	-.--%	43
MODERNA, INC.	+49.12%	5.46TCr
IQVIA HOLDINGS INC.	-4.82%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+15.63%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.80%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.41%	1.22TCr
BIO-TECHNE CORPORATION	+2.23%	1.22TCr
MEDPACE HOLDINGS, INC.	+27.15%	1.19TCr

Other Biotechnology & Medical Research